NEWS HIGHLIGHTS
Published Studies Related to Visudyne (Verteporfin)
Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). [2009.06]
BACKGROUND: To report the outcome of best-corrected visual acuity (BCVA), near visual acuity (NVA), contrast sensitivity (CS) and vision-related quality of life (VRQOL) in patients 2 years after undergoing photodynamic therapy (PDT) or full macular translocation (FMT) for the treatment of neovascular age-related macular degeneration (AMD)... CONCLUSIONS: FMT can stabilise BCVA and improve NVA over a period of 2 years in patients with subfoveal classic CNV secondary to neovascular AMD, whereas a decrease of BCVA and NVA was found in the PDT group. CS did not differ between FMT and PDT. A significant increase of VRQOL scores was only found in the FMT group and not in the PDT group. FMT seems to be a therapeutic approach that can increase visual function resulting in an improvement of patient's VRQOL, but exhibits a higher number of severe complications compared to PDT.
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. [2009.01]
OBJECTIVE: The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV... CONCLUSIONS: In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Rates of serious adverse events were low. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. [2008.10]
OBJECTIVE: To evaluate the efficacy of photodynamic therapy (PDT) with half-dose verteporfin for treating acute central serous chorioretinopathy (CSC)... CONCLUSIONS: Photodynamic therapy with half-dose verteporfin is effective in treating acute symptomatic CSC, resulting in a higher proportion of patients with absence of exudative macular detachment and better visual acuity compared with placebo.
Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy One-Year Results of a Randomized Controlled Trial. [2008.06.04]
OBJECTIVE: To evaluate the efficacy of photodynamic therapy (PDT) with half-dose verteporfin for treating acute central serous chorioretinopathy (CSC)... CONCLUSIONS: Photodynamic therapy with half-dose verteporfin is effective in treating acute symptomatic CSC, resulting in a higher proportion of patients with absence of exudative macular detachment and better visual acuity compared with placebo.
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. [2008.05]
PURPOSE: To assess the efficacy and adverse-events profile of combined treatment with ranibizumab and verteporfin photodynamic therapy (PDT) in patients with predominantly classic choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration. DESIGN: Two-year, multicenter, randomized, single-masked, controlled study... CONCLUSIONS: Through two years, ranibizumab + PDT was more effective than PDT alone and had a low rate of associated adverse events.
Clinical Trials Related to Visudyne (Verteporfin)
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) [Terminated]
The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination
with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of
fluid within the eye and thereby stabilizing or improving vision when compared to Macugen
alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be
eligible for PDT.
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) [Active, not recruiting]
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne
followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne
followed by Lucentis-Dexamethasone triple therapy [within 2 hours]) reduces retreatment rates
compared with Lucentis monotherapy while maintaining similar vision outcomes and an
acceptable safety profile.
VisudyneŽ in Occult (VIO) [Completed]
The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult
with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable
safety profile, significantly reduce the risk of vision loss compared with placebo (sham
treatment).
VERITAS: A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib [Active, not recruiting]
To evaluate the safety and efficacy of the combination treatments in wet age-related macular
degeneration. The combination treatment consists of verteporfin photodynamic therapy and
either triamcinolone acetonide or pegaptanib added as an intravitreal injection.
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration [Completed]
To determine whether VISUDYNE therapy in combination with 4 mg intravitreal triamcinolone
will reduce the average loss from baseline of best corrected visual acuity (BCVA) as compared
with Visudyne therapy without intravitreal triamcinolone at 12 months in subjects with occult
subfoveal and minimally classic subfoveal CNV secondary to AMD. The intravitreal
triamcinolone will be given as either a 1 mg or 4 mg dose. This study will also evaluate the
safety of Visudyne therapy in combination with intravitreal triamcinolone. An interim
statistical readout will be performed when the first 60 patients have completed 6 months of
follow-up evaluation.
|
